RT Journal Article
SR Electronic
T1 Overexpression of Fibroblast Activation Protein (FAP) in stroma of proliferative inflammatory atrophy (PIA) and primary adenocarcinoma of the prostate
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.04.24305338
DO 10.1101/2024.04.04.24305338
A1 Caramella-Pereira, Fernanda
A1 Zheng, Qizhi
A1 Hicks, Jessica L.
A1 Roy, Sujayita
A1 Jones, Tracy
A1 Pomper, Martin
A1 Antony, Lizamma
A1 Meeker, Alan K.
A1 Yegnasubramanian, Srinivasan
A1 De Marzo, Angelo M.
A1 Brennen, W. Nathaniel
YR 2024
UL http://medrxiv.org/content/early/2024/04/05/2024.04.04.24305338.abstract
AB Fibroblast activation protein (FAP) is a serine protease upregulated at sites of tissue remodeling and cancer that represents a promising therapeutic and molecular imaging target. In prostate cancer, studies of FAP expression using tissue microarrays are conflicting, such that its clinical potential is unclear. Furthermore, little is known regarding FAP expression in benign prostatic tissues. Here we demonstrated, using a novel iterative multiplex IHC assay in standard tissue sections, that FAP was nearly absent in normal regions, but was increased consistently in regions of proliferative inflammatory atrophy (PIA). In carcinoma, FAP was expressed in all cases, but was highly heterogeneous. High FAP levels were associated with increased pathological stage and cribriform morphology. We verified that FAP levels in cancer correlated with CD163+ M2 macrophage density. In this first report to quantify FAP protein in benign prostate and primary tumors, using standard large tissue sections, we clarify that FAP is present in all primary prostatic carcinomas, supporting its potential clinical relevance. The finding of high levels of FAP within PIA supports the injury/regeneration model for its pathogenesis and suggests that it harbors a protumorigenic stroma. Yet, high levels of FAP in benign regions could lead to false positive FAP-based molecular imaging results in clinically localized prostate cancer.Competing Interest StatementAMDM is a paid consultant/advisor to Merck and Cepheid and has received research funding from Janssen and Myriad. SY receives research funding to his institution from Bristol-Myers Squibb and Celgene Janssen and Cepheid and has served as a consultant for Cepheid. He owns founders equity in Brahm Astra Therapeutics and Digital Harmonic. MCM is a paid consultant to Clovis and Exelixis. WNB has received a monetary gift from Imago Biosciences a subsidiary of Merck & Co. Inc.; sponsored research funding from Transcenta Holding and owns founders equity in ABIDA Bio, LLCFunding StatementThis work is supported by NIH/NCI U54 CA274370 (AMDM and SY) NIH/ National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPORE) in Prostate Cancer grant P50CA58236 (AMDM), NIH/NCI grant U01 CA196390 (AMDM and SY), R01 CA255259-04(WNB), R01 CA279993-01A1 (WNB), U.S. Department of Defense Prostate Cancer Research Program (PCRP), W81XWH-18-2-0015 (AMDM), NIH/NIBIB P41 EB024495 (MP), The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Oncology Tissue Services Laboratory is supported by NIH/NCI grant P30 CA006973 and The Patrick C. Walsh Prostate Cancer Research Fund at Johns Hopkins (AMDM and SY).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Johns Hopkins school of Medicine gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors